POET · NASDAQ · STOCK
POET Technologies (POET) Stock Analysis
$6.97
52W $3.87 – $20.81
52/100
$920.13M
-9.8
0.84
Is POET Bullish or Bearish?
Mixed.
Innellis AI committee rates POET Technologies Inc. (POET) Watch with a composite score of 52/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.34 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.66 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 202.3% YoY -- genuine top-line momentum — Growth
- Low leverage (debt-to-equity 0.04) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -19.6% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- RSI at 30 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 91%
of 287 Technology peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.5x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 202.3% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bearish
31
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.04) -- balance sheet can absorb a shock
− Bollinger bandwidth of 18.0% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
53
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 52.9 to 51.7.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: score 39->31 (-8); +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
29.6
Oversold
MACD Histogram
-0.056
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Mixed
Support
$6.29
Resistance
$7.56
Bollinger %B
0.03
Inside Bands
Price vs Moving Averages
EMA 9
$7.42
Below
EMA 21
$7.60
Below
EMA 50
$7.96
Below
EMA 200
$8.13
Below
Fundamental Analysis
Valuation
83
Growth
38
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-9.8×
P/B Ratio
1.34×
PEG Ratio
2.01
Dividend Yield
0.00%
52W High
$20.81
52W Low
$3.87
Quality & Growth
ROE
-3425.8%
ROA
-1916.3%
Gross Margin
-6797.7%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of -9.8 (inexpensive relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of 2.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -34.3%; Return on assets of -19.2%; Net margin of -4420.7%; Gross margin of -68.0%; Current ratio of 24.46 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is negative (-0.25); Most recent quarter beat estimates by 14.2%; EPS growth decelerating (+75.0% -> +12.5% QoQ); Average YoY EPS growth of 63.2%; Analyst estimates falling over recent quarters
Get the Full POET Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →